Insight Molecular Diagnostics Inc. (NASDAQ: IMDX)

Insight Molecular Diagnostics Inc. is a diagnostics technology company focused on expanding access to molecular diagnostic testing for organ transplant rejection and oncology applications. The company develops and commercializes test kits that enable hospitals, transplant centers and laboratories to perform testing in house, thereby decentralizing the traditional send out model. Its primary near term market is organ transplant rejection monitoring, with a secondary focus on oncology therapy selection and monitoring.

The company generates revenue through the sale of its GraftAssure family of products, including the CLIA certified GraftAssureCore laboratory developed test performed at its Franklin, Tennessee facility, the research use only GraftAssureIQ kit, and the investigational GraftAssureDx IVD kit under development. It also earns fees from laboratory services provided to life sciences and biotechnology companies for assay development and clinical testing. Revenue is recognized when tests are performed or kits are delivered, and the company seeks reimbursement from Medicare, private payers and direct customers for its offerings.

Insight Molecular Diagnostics Inc. operates in a highly competitive molecular diagnostics landscape where firms such as CareDx Inc., Natera Inc., Transplant Genomics, Omixon Inc. and Devyser offer competing liquid biopsy and donor derived cell free DNA based transplant rejection tests. The company differentiates itself by selling test kits that allow local laboratories to run assays on digital PCR instruments, which provides attractive sample economics, fast turnaround times and native absolute quantification. Its intellectual property portfolio covering organ transplant, oncology therapy selection and monitoring, together with strategic partnerships such as the agreement with Bio Rad Laboratories, supports its position as an innovator in decentralized testing.

The company serves hospitals, transplant centers, clinical laboratories, physicians including surgeons, nephrologists and oncologists, researchers, pathologists, lab directors and medical directors. It also provides laboratory services to life sciences and biotechnology companies needing assay development and testing support. While specific customer names are not disclosed, the company has reported sales of GraftAssureIQ kits to a research laboratory customer and a specimen collection agreement with a national reference lab provider.